Search

© 2005. The American Astronomical Society. All rights reserved. We thank an unknown referee for his/her criticism. GALEX (Galaxy Evolution Explorer) is a NASA Small Explorer, launched in 2003 April. We gratefully acknowledge NASA’s support for construction, operation, and science analysis for the GALEX mission, developed in cooperation with the Centre National d’Etudes Spatiales of France and the Korean Ministry of Science and Technology. The authors would like to take this opportunity to thank the members of the GALEX SODA team for their valiant efforts in the timely reduction of the complex observational data set covering the full expanse of the Virgo Cluster., We study the UV properties of a volume-limited sample of early-type galaxies in the Virgo Cluster combining new GALEX far-ultraviolet (1530 Å) and near-ultraviolet (2310 Å) data with spectrophotometric data available at other wavelengths. The sample includes 264 elliptical, lenticular, and dwarf galaxies spanning a large range in luminosity (M_B ≤ -15). While the NUV to optical or near-IR color-magnitude relations (CMRs) are similar to those observed at optical wavelengths, with a monotonic reddening of the color index with increasing luminosity, the (FUV - V) and (FUV - H) CMRs show a discontinuity between massive and dwarf objects. An even more pronounced dichotomy is observed in the (FUV - NUV) CMR. For elliptical galaxies, the (FUV - NUV) color becomes bluer with increasing luminosity and with increasing reddening of the optical or near-IR color indices. For the dwarfs, the opposite trend is observed. These observational evidences are consistent with the idea that the UV emission is dominated by hot, evolved stars in giant systems, while in dwarf ellipticals residual star formation activity is more common., Depto. de Física de la Tierra y Astrofísica, Fac. de Ciencias Físicas, TRUE, pub

Background: The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum-based chemotherapy and baseline disease. Methods: Patients were randomized 2:1 to receive either oral rucaparib at a dosage of 600 mg twice daily or placebo. Investigator-assessed PFS was assessed in prespecified, nested cohorts: BRCA-mutated, homologous recombination deficient (HRD; BRCA mutated or wild-type BRCA/high loss of heterozygosity), and the intent-to-treat (ITT) population. Results: Median PFS for patients in the ITT population with a complete response to most recent platinum-based chemotherapy was 11.1 months in the rucaparib arm (126 patients) versus 5.6 months in the placebo arm (64 patients) (HR, 0.33 [95% CI, 0.23–0.48]), and in patients with a partial response (249 vs. 125), it was 9.0 versus 5.3 months (HR, 0.38 [0.30–0.49]). In subgroups of the ITT population based on baseline disease, median PFS was 8.2 versus 5.3 months (HR, 0.40 [0.28–0.57]) in patients with measurable disease (141 rucaparib vs. 66 placebo), 10.4 versus 4.5 months (HR, 0.31 [0.20–0.48]) in those with nonmeasurable but evaluable disease (104 vs. 56), and 14.1 versus 7.3 months (HR, 0.35 [0.24–0.51]) in those with no residual disease (130 vs. 67). Across subgroups, significantly longer median PFS was observed with rucaparib versus placebo in the BRCA-mutated and HRD cohorts. Objective responses were reported in patients with measurable disease and in patients with nonmeasurable but evaluable baseline disease. Safety was consistent across subgroups. Conclusion: Rucaparib maintenance treatment provided clinically meaningful efficacy benefits across subgroups based on response to last platinum-based chemotherapy or baseline disease.

Introduction In ARIEL3 (NCT01968213), the poly(adenosine diphosphate-ribose) polymerase inhibitor rucaparib significantly improved progression-free survival versus placebo regardless of biomarker status when used as maintenance treatment for recurrent ovarian cancer. The aim of the current analyses was to evaluate the efficacy and safety of rucaparib in subgroups based on progression-free interval following penultimate platinum, number of prior chemotherapies, and prior use of bevacizumab. Methods Patients were randomized 2:1 to rucaparib 600 mg twice daily or placebo. Within subgroups, progression-free survival was assessed in prespecified, nested cohorts: BRCA-mutant, homologous recombination deficient (BRCA-mutant or wild-type BRCA/high genomic loss of heterozygosity), and the intent-to-treat population. Results In the intent-to-treat population, median investigator-assessed progression-free survival was 8.2 months with rucaparib versus 4.1 months with placebo (n=151 vs n=76; HR 0.33, 95% CI 0.24 to 0.46, p<0.0001) for patients with progression-free interval 6 to =12 months, and 13.6 versus 5.6 months (n=224 vs n=113; HR 0.39, 95% CI 0.30 to 0.52, p<0.0001) for those with progression-free interval >12 months. Median progression-free survival was 10.4 versus 5.4 months (n=231 vs n=124; HR 0.42, 95% CI 0.32 to 0.54, p<0.0001) for patients who had received two prior chemotherapies, and 11.1 versus 5.3 months (n=144 vs n=65; HR 0.28, 95% CI 0.19 to 0.41, p<0.0001) for those who had received =3 prior chemotherapies. Median progression-free survival was 10.3 versus 5.4 months (n=83 vs n=43; HR 0.42, 95% CI 0.26 to 0.68, p=0.0004) for patients who had received prior bevacizumab, and 10.9 versus 5.4 months (n=292 vs n=146; HR 0.35, 95% CI 0.28 to 0.45, p<0.0001) for those who had not. Across subgroups, median progression-free survival was also significantly longer with rucaparib versus placebo in the BRCA-mutant and homologous recombination deficient co

Background: In the phase 3 trial ARIEL3, maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib provided clinical benefit versus placebo for patients with recurrent, platinum-sensitive ovarian cancer. Here, we evaluate the impact of age on the clinical utility of rucaparib in ARIEL3. Methods: Patients with platinum-sensitive, recurrent ovarian carcinoma with ≥2 prior platinum-based chemotherapies who responded to their last platinum-based therapy were enrolled in ARIEL3 and randomized 2:1 to rucaparib 600 mg twice daily or placebo. Exploratory, post hoc analyses of progression-free survival (PFS), patient-centered outcomes (quality-adjusted PFS [QA-PFS] and quality-adjusted time without symptoms or toxicity [Q-TWiST]), and safety were conducted in three age subgroups (<65 years, 65–74 years, and ≥75 years). Results: Investigator-assessed PFS was significantly longer with rucaparib than placebo in patients aged <65 years (rucaparib n = 237 vs placebo n = 117; median, 11.1 vs 5.4 months; hazard ratio [HR]: 0.33 [95% confidence interval (95% CI) 0.25–0.43]; P < 0.0001) and 65–74 years (n = 113 vs n = 64; median, 8.3 vs 5.3 months; HR 0.43 [95% CI 0.29–0.63]; P < 0.0001) and numerically longer in patients aged ≥75 years (n = 25 vs n = 8; median, 9.2 vs 5.5 months; HR 0.47 [95% CI 0.16–1.35]; P = 0.1593). QA-PFS and Q-TWiST were significantly longer with rucaparib than placebo across all age subgroups. Safety of rucaparib was generally similar across the age subgroups. Conclusions: Efficacy, patient-centered outcomes, and safety of rucaparib were similar between age subgroups, indicating that all eligible women with recurrent ovarian cancer should be offered this therapeutic option, irrespective of age. https://clinicaltrials.gov/ct2/show/NCT01968213.

Background: In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival versus placebo. Here, we report prespecified, investigator-assessed, exploratory post-progression endpoints and updated safety data. Methods: In this ongoing (enrolment complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 who had received at least two previous platinum-based chemotherapy regimens and responded to their last platinum-based regimen were randomly assigned (2:1) to oral rucaparib (600 mg twice daily) or placebo in 28-day cycles using a computer-generated sequence (block size of six with stratification based on homologous recombination repair gene mutation status, progression-free interval following penultimate platinum-based regimen, and best response to most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary endpoint of investigator-assessed progression-free survival has been previously reported. Prespecified, exploratory outcomes of chemotherapy-free interval (CFI), time to start of first subsequent therapy (TFST), time to disease progression on subsequent therapy or death (PFS2), and time to start of second subsequent therapy (TSST) and updated safety were analysed (visit cutoff Dec 31, 2017). Efficacy analyses were done in all patients randomised to three nested cohorts: patients with BRCA mutations, patients with homologous recombination deficiencies, and the intention-to-treat population. Safety analyses included all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT01968213. Findings: Between April 7, 2014, and July 19, 2016, 564 patients were enrolled and randomly assigned to r

BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC.Patients and methodsExpression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies.ResultsExpression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years.ConclusionThe OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS: Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS: Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. CONCLUSION: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.

BackgroundMedian overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC.Patients and methodsExpression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies.ResultsExpression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years.ConclusionThe OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.

Background: In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival versus placebo. Here, we report prespecified, investigator-assessed, exploratory post-progression endpoints and updated safety data. Methods: In this ongoing (enrolment complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 who had received at least two previous platinum-based chemotherapy regimens and responded to their last platinum-based regimen were randomly assigned (2:1) to oral rucaparib (600 mg twice daily) or placebo in 28-day cycles using a computer-generated sequence (block size of six with stratification based on homologous recombination repair gene mutation status, progression-free interval following penultimate platinum-based regimen, and best response to most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary endpoint of investigator-assessed progression-free survival has been previously reported. Prespecified, exploratory outcomes of chemotherapy-free interval (CFI), time to start of first subsequent therapy (TFST), time to disease progression on subsequent therapy or death (PFS2), and time to start of second subsequent therapy (TSST) and updated safety were analysed (visit cutoff Dec 31, 2017). Efficacy analyses were done in all patients randomised to three nested cohorts: patients with BRCA mutations, patients with homologous recombination deficiencies, and the intention-to-treat population. Safety analyses included all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT01968213. Findings: Between April 7, 2014, and July 19, 2016, 564 patients were enrolled and randomly assigned to r

Background: In the phase 3 trial ARIEL3, maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib provided clinical benefit versus placebo for patients with recurrent, platinum-sensitive ovarian cancer. Here, we evaluate the impact of age on the clinical utility of rucaparib in ARIEL3. Methods: Patients with platinum-sensitive, recurrent ovarian carcinoma with ≥2 prior platinum-based chemotherapies who responded to their last platinum-based therapy were enrolled in ARIEL3 and randomized 2:1 to rucaparib 600 mg twice daily or placebo. Exploratory, post hoc analyses of progression-free survival (PFS), patient-centered outcomes (quality-adjusted PFS [QA-PFS] and quality-adjusted time without symptoms or toxicity [Q-TWiST]), and safety were conducted in three age subgroups (<65 years, 65–74 years, and ≥75 years). Results: Investigator-assessed PFS was significantly longer with rucaparib than placebo in patients aged <65 years (rucaparib n = 237 vs placebo n = 117; median, 11.1 vs 5.4 months; hazard ratio [HR]: 0.33 [95% confidence interval (95% CI) 0.25–0.43]; P < 0.0001) and 65–74 years (n = 113 vs n = 64; median, 8.3 vs 5.3 months; HR 0.43 [95% CI 0.29–0.63]; P < 0.0001) and numerically longer in patients aged ≥75 years (n = 25 vs n = 8; median, 9.2 vs 5.5 months; HR 0.47 [95% CI 0.16–1.35]; P = 0.1593). QA-PFS and Q-TWiST were significantly longer with rucaparib than placebo across all age subgroups. Safety of rucaparib was generally similar across the age subgroups. Conclusions: Efficacy, patient-centered outcomes, and safety of rucaparib were similar between age subgroups, indicating that all eligible women with recurrent ovarian cancer should be offered this therapeutic option, irrespective of age. https://clinicaltrials.gov/ct2/show/NCT01968213.

PURPOSE To investigate quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of the phase III ARIEL3 study of rucaparib maintenance treatment versus placebo. PATIENTS AND METHODS Patients with platinum-sensitive, recurrent ovarian carcinoma were randomly assigned to rucaparib (600 mg twice per day) or placebo. QA-PFS was calculated as progression-free survival function 3 the 3-level version of the EQ-5D questionnaire (EQ-5D-3L) index score function. Q-TWiST analyses were performed defining TOX as the mean duration in which a patient experienced grade $ 3 treatment-emergent adverse events (TEAEs) or the mean duration in which a patient experienced grade $ 2 TEAEs of nausea, vomiting, fatigue, and asthenia. Q-TWiST was calculated as mTOX 3 TOX 1 TWiST, with mTOX calculated using EQ-5D-3L data. RESULTS The visit cutoff was Apr 15, 2017. Mean QA-PFS was significantly longer with rucaparib versus placebo in the intent-to-treat (ITT) population (375 randomly assigned to rucaparib v 189 randomly assigned to placebo; difference, 6.28 months [95% CI, 4.85 to 7.47 months]); BRCA-mutant cohort (130 rucaparib v 66 placebo; 9.37 months [95% CI, 6.65 to 11.85 months]); homologous recombination deficient (HRD) cohort (236 rucaparib v 118 placebo; 7.93 months [95% CI, 5.93 to 9.53 months]); and BRCA wild-type/loss of heterozygosity (LOH) low patient subgroup (107 rucaparib v 54 placebo; 2.71 months [95% CI, 0.31 to 4.44 months]). With TOX defined using grade $ 3 TEAEs, the difference in mean Q-TWiST (rucaparib v placebo) was 6.88 months (95% CI, 5.71 to 8.23 months), 9.73 months (95% CI, 7.10 to 11.94 months), 8.11 months (95% CI, 6.36 to 9.49 months), and 3.35 months (95% CI, 1.66 to 5.40 months) in the ITT population, BRCA-mutant cohort, HRD cohort, and BRCA wild-type/LOH low patient subgroup, respectively. Q-TWiST with TOX defined using select grade $ 2 TEAEs also consistently favor

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.

Contains fulltext : 177333.pdf (publisher's version ) (Open Access), OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. METHODS AND MATERIALS: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. RESULTS: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and p

VEGFR1 rs9582036 and rs9554320 were previously reported the association with sunitinib progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Hereafter, the association of both single nucleotide polymorphisms (SNPs) with PFS/OS was confirmed in two independent mRCC cohorts. The aim of the current study was to validate the associations of both SNPs with sunitinib outcome in three independent well-characterized cohorts (SUTOX, CCF and SOGUG) including 286 sunitinib-treated mRCC patients, as well as to perform a meta-analysis of current and published data combined. We found that rs9582036 and rs9554320 showed a significant association with sunitinib PFS in the CCF cohort (HR: 0.254, 95%CI: 0.092-0.703; P=0.008 and HR: 0.430, 95%CI: 0.200- 0.927

Contains fulltext : 177333.pdf (publisher's version ) (Open Access), OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. METHODS AND MATERIALS: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. RESULTS: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and p

Contains fulltext : 177333.pdf (publisher's version ) (Open Access), OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in identifying better biomarkers for personalized treatment. EuroTARGET aims to identify and characterize host- and tumor-related biomarkers for prediction of response to tyrosine kinase inhibitor therapy in mRCC. Here, we describe the EuroTARGET mRCC patient cohort. METHODS AND MATERIALS: EuroTARGET is a European collaborative project designed as an observational study for which patients with mRCC were recruited prospectively in 62 centers. In addition, 462 patients with mRCC from previous studies were included. Detailed clinical information (baseline and follow-up) from all patients was entered in web-based case record forms. Blood was collected for germline DNA and pharmacokinetic/pharmacodynamic analyses and, where available, fresh-frozen tumor material was collected to perform tumor DNA, RNA, kinome, and methylome analyses. RESULTS: In total, 1,210 patients with mRCC were included. Of these, 920 received a tyrosine kinase inhibitor as first-line targeted treatment (sunitinib [N = 713, 78%], sorafenib [N = 41, 4%], or pazopanib [N = 166, 18%]) and had at least 6 months of outcome assessment (median follow-up 15.3 months [interquartile range: 8.5-30.2 months]). Germline DNA samples were available from 824 of these patients, fresh-frozen tumor material from 142 patients, fresh-frozen normal kidney tissue from 95 patients, and tissue microarrays created from formalin-fixed paraffin-embedded tumor material from 247 patients. Of the 920 patients, germline DNA variant chip data were successfully generated for 811 patients (Illumina HumanOmniExpress BeadChip). For 80 patients, next-generation exome sequencing of germline and tumor DNA was performed, tumor RNA sequencing was performed for 124 patients, kinome activity measured and p

Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0-1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients wit

Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. Methods In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0–1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients wi

Purpose: Earlier, the association of single nucleotide polymorphisms (SNPs) with toxicity and efficacy of sunitinib has been explored in patients with metastatic renal cell

Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number-based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03-0.81; Padj = 0.03). We found that loss at 6q24.2-26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01-0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48-0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61-0.90, log-rank P = 0.002) and 675 high-FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61-0.96, log-rank P = 0.02) available from the online tool KM-plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2-26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side-effects and improve quality of life.

BACKGROUND: We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC). METHODS: The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib (N=729, study 2) and an observational study of sunitinib-treated patients (N=89, study 3). RESULTS: In study 1, four SNPs showed nominally significant association (P≤0.05) with OS; two of these SNPs (rs1126647, rs4073) in IL8 were associated (P≤0.05) with OS in study 2. Because rs1126647 and rs4073 were highly correlated, only rs1126647 was evaluated in study 3, which also showed association (P≤0.05). In the combined data, rs1126647 was associated with OS after conservative multiple-test adjustment (P=8.8 × 10(-5); variant vs reference allele hazard ratio 1.32, 95% confidence interval: 1.15-1.52), without evidence for heterogeneity of effects between studies or between pazopanib- and sunitinib-treated patients. CONCLUSIONS: Variant alleles of IL8 polymorphisms are associated with poorer survival outcomes in pazopanib- or sunitinib-treated patients with aRCC. These findings provide insight in aRCC prognosis and may advance our thinking in development of new therapies.

We identified differentially expressed microRNAs in MRCC patients presenting marked sensitivity or resistance to sunitinib. MiR-942 was the best predictor of efficacy. We describe a novel paracrine mechanism through which high miR-942 levels in MRCC cells up-regulates MMP-9 and VEGF secretion to enhance endothelial migration and sunitinib resistance. Our results support further validation of these miRNA in clinical confirmatory studies.

We present a detailed study of the Galaxy Evolution Explorer's photometric catalogs with special focus on the statistical properties of the All-sky and Medium Imaging Surveys. We introduce the concept of primaries to resolve the issue of multiple detections and follow a geometric approach to define clean catalogs with well-understood selection functions. We cross-identify the GALEX sources (GR2+3) with Sloan Digital Sky Survey (DR6) observations, which indirectly provides an invaluable insight about the astrometric model of the UV sources and allows us to revise the band merging strategy. We derive the formal description of the GALEX footprints as well as their intersections with the SDSS coverage along with analytic calculations of their areal coverage. The crossmatch catalogs are made available for the public. We conclude by illustrating the implementation of typical selection criteria in SQL for catalog subsets geared toward statistical analyses, e.g., correlation and luminosity function studies., Comment: 12 pages, 15 figures, accepted to ApJ

We present a detailed study of the Galaxy Evolution Explorer's photometric catalogs with special focus on the statistical properties of the All-sky and Medium Imaging Surveys. We introduce the concept of primaries to resolve the issue of multiple detections and follow a geometric approach to define clean catalogs with well-understood selection functions. We cross-identify the GALEX sources (GR2+3) with Sloan Digital Sky Survey (DR6) observations, which indirectly provides an invaluable insight about the astrometric model of the UV sources and allows us to revise the band merging strategy. We derive the formal description of the GALEX footprints as well as their intersections with the SDSS coverage along with analytic calculations of their areal coverage. The crossmatch catalogs are made available for the public. We conclude by illustrating the implementation of typical selection criteria in SQL for catalog subsets geared toward statistical analyses, e.g., correlation and luminosity function studies., Comment: 12 pages, 15 figures, accepted to ApJ

We present the results from the analysis of optical spectra of 31 Halpha-selected regions in the extended UV (XUV) disks of M83 (NGC5236) and NGC4625 recently discovered by GALEX. The spectra were obtained using IMACS at Las Campanas Observatory 6.5m Magellan I telescope and COSMIC at the Palomar 200-inch telescope, respectively for M83 and NGC4625. The line ratios measured indicate nebular oxygen abundances (derived from the R23 parameter) of the order of Zsun/5-Zsun/10. For most emission-line regions analyzed the line fluxes and ratios measured are best reproduced by models of photoionization by single stars with masses in the range 20-40 Msun and oxygen abundances comparable to those derived from the R23 parameter. We find indications for a relatively high N/O abundance ratio in the XUV disk of M83. Although the metallicities derived imply that these are not the first stars formed in the XUV disks, such a level of enrichment could be reached in young spiral disks only 1 Gyr after these first stars would have formed. The amount of gas in the XUV disks allow maintaining the current level of star formation for at least a few Gyr., Comment: 52 pages, 8 tables, 7 figures, accepted for publication in ApJ

We present a study of the morphological nature of redshift z~0.7 star-forming galaxies using a combination of HST/ACS, GALEX and ground-based images of the COSMOS field. Our sample consists of 8,146 galaxies, 5,777 of which are detected in the GALEX near-ultraviolet band down to a limiting magnitude of 25.5 (AB). We make use of the UV to estimate star formation rates, correcting for the effect of dust using the UV-slope, and compute, from the ACS F814W images, the C,A,S,G,M20 morphological parameters for all objects in our sample. We observe a morphological bimodality in the galaxy population and show that it has a strong correspondence with the FUV - g color bimodality. We conclude that UV-optical color predominantly evolves concurrently with morphology. We observe many of the most star-forming galaxies to have morphologies approaching that of early-type galaxies, and interpret this as evidence that strong starburst events are linked to bulge growth and constitute a process through which galaxies can be brought from the blue to the red sequence while simultaneously modifying their morphology accordingly. We conclude that the red sequence has continued growing at z~<0.7. We also observe z~0.7 galaxies to have physical properties similar to that of local galaxies, except for higher star formation rates. Whence we infer that the dimming of star-forming galaxies is responsible for most of the evolution in the star formation rate density of the Universe since that redshift, although our data are also consistent with a mild number evolution. [abridged], Comment: 29 pages including 22 figures. Accepted for publication in ApJS COSMOS Special Issue. A copy of the paper with high resolution figures is available at http://www.astro.columbia.edu/~michel/galex_cosmos_paper.pdf

We study the ultraviolet to far-infrared (hereafter UV-to-IR) SEDs of a sample of intermediate redshift (0.2 < z < 0.7) UV-selected galaxies from the ELAIS-N1 and ELAIS-N2 fields by fitting a multi-wavelength dataset to a library of GRASIL templates. Star formation related properties of the galaxies are derived from the library of models by using the Bayesian statistics. We find a decreasing presence of galaxies with low attenuation and low total luminosity as redshift decreases, which does not hold for high total luminosity galaxies. In addition the dust attenuation of low mass galaxies increases as redshift decreases, and this trend seems to disappear for galaxies with M* > 10^11 M_sun. This result is consistent with a mass dependent evolution of the dust to gas ratio, which could be driven by a mass dependent efficiency of star formation in star forming galaxies. The specific star formation rates (SSFR) decrease with increasing stellar mass at all redshifts, and for a given stellar mass the SSFR decreases with decreasing redshift. The differences in the slope of the M*--SSFR relation found between this work and others at similar redshift could be explained by the adopted selection criteria of the samples which, for a UV selected sample, favours blue, star forming galaxies., Comment: 21 figures, accepted for publication in ApJ

We study the ultraviolet to far-infrared (hereafter UV-to-IR) SEDs of a sample of intermediate redshift (0.2 < z < 0.7) UV-selected galaxies from the ELAIS-N1 and ELAIS-N2 fields by fitting a multi-wavelength dataset to a library of GRASIL templates. Star formation related properties of the galaxies are derived from the library of models by using the Bayesian statistics. We find a decreasing presence of galaxies with low attenuation and low total luminosity as redshift decreases, which does not hold for high total luminosity galaxies. In addition the dust attenuation of low mass galaxies increases as redshift decreases, and this trend seems to disappear for galaxies with M* > 10^11 M_sun. This result is consistent with a mass dependent evolution of the dust to gas ratio, which could be driven by a mass dependent efficiency of star formation in star forming galaxies. The specific star formation rates (SSFR) decrease with increasing stellar mass at all redshifts, and for a given stellar mass the SSFR decreases with decreasing redshift. The differences in the slope of the M*--SSFR relation found between this work and others at similar redshift could be explained by the adopted selection criteria of the samples which, for a UV selected sample, favours blue, star forming galaxies., Comment: 21 figures, accepted for publication in ApJ

We study the ultraviolet to far-infrared (hereafter UV-to-IR) SEDs of a sample of intermediate redshift (0.2 < z < 0.7) UV-selected galaxies from the ELAIS-N1 and ELAIS-N2 fields by fitting a multi-wavelength dataset to a library of GRASIL templates. Star formation related properties of the galaxies are derived from the library of models by using the Bayesian statistics. We find a decreasing presence of galaxies with low attenuation and low total luminosity as redshift decreases, which does not hold for high total luminosity galaxies. In addition the dust attenuation of low mass galaxies increases as redshift decreases, and this trend seems to disappear for galaxies with M* > 10^11 M_sun. This result is consistent with a mass dependent evolution of the dust to gas ratio, which could be driven by a mass dependent efficiency of star formation in star forming galaxies. The specific star formation rates (SSFR) decrease with increasing stellar mass at all redshifts, and for a given stellar mass the SSFR decreases with decreasing redshift. The differences in the slope of the M*--SSFR relation found between this work and others at similar redshift could be explained by the adopted selection criteria of the samples which, for a UV selected sample, favours blue, star forming galaxies., Comment: 21 figures, accepted for publication in ApJ

We present the results from the analysis of optical spectra of 31 Halpha-selected regions in the extended UV (XUV) disks of M83 (NGC5236) and NGC4625 recently discovered by GALEX. The spectra were obtained using IMACS at Las Campanas Observatory 6.5m Magellan I telescope and COSMIC at the Palomar 200-inch telescope, respectively for M83 and NGC4625. The line ratios measured indicate nebular oxygen abundances (derived from the R23 parameter) of the order of Zsun/5-Zsun/10. For most emission-line regions analyzed the line fluxes and ratios measured are best reproduced by models of photoionization by single stars with masses in the range 20-40 Msun and oxygen abundances comparable to those derived from the R23 parameter. We find indications for a relatively high N/O abundance ratio in the XUV disk of M83. Although the metallicities derived imply that these are not the first stars formed in the XUV disks, such a level of enrichment could be reached in young spiral disks only 1 Gyr after these first stars would have formed. The amount of gas in the XUV disks allow maintaining the current level of star formation for at least a few Gyr., Comment: 52 pages, 8 tables, 7 figures, accepted for publication in ApJ

We present a study of the morphological nature of redshift z~0.7 star-forming galaxies using a combination of HST/ACS, GALEX and ground-based images of the COSMOS field. Our sample consists of 8,146 galaxies, 5,777 of which are detected in the GALEX near-ultraviolet band down to a limiting magnitude of 25.5 (AB). We make use of the UV to estimate star formation rates, correcting for the effect of dust using the UV-slope, and compute, from the ACS F814W images, the C,A,S,G,M20 morphological parameters for all objects in our sample. We observe a morphological bimodality in the galaxy population and show that it has a strong correspondence with the FUV - g color bimodality. We conclude that UV-optical color predominantly evolves concurrently with morphology. We observe many of the most star-forming galaxies to have morphologies approaching that of early-type galaxies, and interpret this as evidence that strong starburst events are linked to bulge growth and constitute a process through which galaxies can be brought from the blue to the red sequence while simultaneously modifying their morphology accordingly. We conclude that the red sequence has continued growing at z~<0.7. We also observe z~0.7 galaxies to have physical properties similar to that of local galaxies, except for higher star formation rates. Whence we infer that the dimming of star-forming galaxies is responsible for most of the evolution in the star formation rate density of the Universe since that redshift, although our data are also consistent with a mild number evolution. [abridged], Comment: 29 pages including 22 figures. Accepted for publication in ApJS COSMOS Special Issue. A copy of the paper with high resolution figures is available at http://www.astro.columbia.edu/~michel/galex_cosmos_paper.pdf

We select far-infrared (FIR-60 microns) and far-ultraviolet (FUV-1530 A) samples of nearby galaxies in order to discuss the biases encountered by monochromatic surveys (FIR or FUV). Very different volumes are sampled by each selection and much care is taken to apply volume corrections to all the analyses. The distributions of the bolometric luminosity of young stars are compared for both samples: they are found to be consistent with each other for galaxies of intermediate luminosities but some differences are found for high (>5 10^{10} L_sun) luminosities. The shallowness of the IRAS survey prevents us from securing comparison at low luminosities (<2 10^9 L_sun). The ratio of the total infrared (TIR) luminosity to the FUV luminosity is found to increase with the bolometric luminosity in a similar way for both samples up to 5 10^{10} L_sun. Brighter galaxies are found to have a different behavior according to their selection: the L_TIR/L_FUV ratio of the FUV-selected galaxies brighter than 5 10^{10} L_sun reaches a plateau whereas L_TIR/L_FUV continues to increase with the luminosity of bright galaxies selected in FIR. The volume-averaged specific star formation rate (SFR per unit galaxy stellar mass, SSFR) is found to decrease toward massive galaxies within each selection. The SSFR is found to be larger than that measured for optical and NIR-selected sample over the whole mass range for the FIR selection, and for masses larger than 10^{10} M_sun for the FUV selection. Luminous and massive galaxies selected in FIR appear as active as galaxies with similar characteristics detected at z ~ 0.7., Comment: 32 pages, 9 figures, to be published in the Astrophysical Journal Supplement series dedicated to GALEX results

We combine data from SDSS and the GALEX and Spitzer observatories to create a sample of galaxies observed homogeneously from the UV to the Far-IR. This sample, consisting of ~460 galaxies observed spectroscopically by SDSS provides a multiwavelength (0.15-24 micron) view of obscured and unobscured star formation in nearby (z<0.3) galaxies with SFRs ranging from 0.01 to 100 M_solar/yr. We calculate a robust dust measure from the infrared to UV ratio (IRX) and explore the influence of star formation history (SFH) on the dust-UV color relation (i.e. the IRX-beta relation). We find that the UV colors of galaxies are only weakly dependent on their SFH as measured by the 4000A break. However, we find that the contributions of dust and SFH are distinguishable when colors at widely separated wavelengths (e.g. 0.23-3.6 micron) are introduced. We show this explicitly by recasting the IRX-beta relation as a more general IRX-SFH-color relation, which we examine in different projections. We also determine simple fits to this relation., Comment: 4 pages, 3 figures, accepted by ApJ Letters

We present images, integrated photometry, surface-brightness and color profiles for a total of 1034 nearby galaxies recently observed by the GALEX satellite in its far-ultraviolet (FUV; 1516A) and near-ultraviolet (NUV; 2267A) bands. (...) This data set has been complemented with archival optical, near-infrared, and far-infrared fluxes and colors. We find that the integrated (FUV-K) color provides robust discrimination between elliptical and spiral/irregular galaxies and also among spiral galaxies of different sub-types. Elliptical galaxies with brighter K-band luminosities (i.e. more massive) are redder in (NUV-K) color but bluer in (FUV-NUV) than less massive ellipticals. In the case of the spiral/irregular galaxies our analysis shows the presence of a relatively tight correlation between the (FUV-NUV) color and the total infrared-to-UV ratio. The correlation found between (FUV-NUV) color and K-band luminosity (with lower luminosity objects being bluer than more luminous ones) can be explained as due to an increase in the dust content with galaxy luminosity. The images in this Atlas along with the profiles and integrated properties are publicly available through a dedicated web page at http://nedwww.ipac.caltech.edu/level5/GALEX_Atlas, Comment: 181 pages, 10 figures, accepted for publication in ApJS (abstract abridged)

This work presents the main ultraviolet (UV) and far-infrared (FIR) properties of two samples of nearby galaxies selected from the GALEX ($\lambda = 2315$\AA, hereafter NUV) and IRAS ($\lambda = 60\mu$m) surveys respectively. They are built in order to get detection at both wavelengths for most of the galaxies. Star formation rate (SFR) estimators based on the UV and FIR emissions are compared. Systematic differences are found between the SFR estimators for individual galaxies based on the NUV fluxes corrected for dust attenuation and on the total IR luminosity. A combined estimator based on NUV and IR luminosities seems to be the best proxy over the whole range of values of SFR. Although both samples present similar average values of the birthrate parameter b, their star-formation-related properties are substantially different: NUV-selected galaxies tend to show larger values of $b$ for lower masses, SFRs and dust attenuations, supporting previous scenarios for the star formation history (SFH). Conversely, about 20% of the FIR-selected galaxies show high values of $b$, SFR and NUV attenuation. These galaxies, most of them being LIRGs and ULIRGs, break down the downsizing picture for the SFH, however their relative contribution per unit volume is small in the local Universe. Finally, the cosmic SFR density of the local Universe is estimated in a consistent way from the NUV and IR luminosities., Comment: 43 pages, 13 figures, accepted for publication in Astrophysical Journal Supplement Series

We use \textit{GALEX} (Galaxy Evolution Explorer) near-UV (NUV) photometry of a sample of early-type galaxies selected in \textit{SDSS} (Sloan Digital Sky Survey) to study the UV color-magnitude relation (CMR). $NUV-r$ color is an excellent tracer of even small amounts ($\sim 1$% mass fraction) of recent ($\la 1$ Gyr) star formation and so the $NUV-r$ CMR allows us to study the effect of environment on the recent star formation history. We analyze a volume-limited sample of 839 visually-inspected early-type galaxies in the redshift range $0.05 < z < 0.10$ brighter than $M_{r}$ of -21.5 with any possible emission-line or radio-selected AGN removed to avoid contamination. We find that contamination by AGN candidates and late-type interlopers highly bias any study of recent star formation in early-type galaxies and that, after removing those, our lower limit to the fraction of massive early-type galaxies showing signs of recent star formation is roughly $30 \pm 3%$ This suggests that residual star formation is common even amongst the present day early-type galaxy population. We find that the fraction of UV-bright early-type galaxies is 25% higher in low-density environments. However, the density effect is clear only in the lowest density bin. The blue galaxy fraction for the subsample of the brightest early-type galaxies however shows a very strong density dependence, in the sense that the blue galaxy fraction is lower in a higher density region., Comment: Accepted for publication in ApJ, paper with high-resolution figures can be downloaded at: http://www-astro.physics.ox.ac.uk/~kevins/PAPERS/uv_environment.ps

We have studied ~2100 early-type galaxies in the SDSS DR3 which have been detected by the GALEX Medium Imaging Survey (MIS), in the redshift range 0 < z < 0.11. Combining GALEX UV photometry with corollary optical data from the SDSS, we find that, at a 95 percent confidence level, at least ~30 percent of galaxies in this sample have UV to optical colours consistent with some recent star formation within the last Gyr. In particular, galaxies with a NUV - r colour less than 5.5 are very likely to have experienced such recent star formation, taking into account the possibility of a contribution to NUV flux from the UV upturn phenomenon. We find quantitative agreement between the observations and the predictions of a semi-analytical LCDM hierarchical merger model and deduce that early-type galaxies in the redshift range 0 < z < 0.11 have ~1 to 3 percent of their stellar mass in stars less than 1 Gyr old. The average age of this recently formed population is ~300 to 500 Myrs. We also find that monolithically evolving galaxies, where recent star formation can be driven solely by recycled gas from stellar mass loss, cannot exhibit the blue colours (NUV - r < 5.5) seen in a significant fraction (~30 percent) of our observed sample., Comment: To appear in GALEX dedicated ApJ issue in December 2007 (accepted June 2006). A version with high-resolution figures can be downloaded at http://www-astro.physics.ox.ac.uk/~skaviraj/PAPERS/uv_cmr.pdf

We select far-infrared (FIR-60 microns) and far-ultraviolet (FUV-1530 A) samples of nearby galaxies in order to discuss the biases encountered by monochromatic surveys (FIR or FUV). Very different volumes are sampled by each selection and much care is taken to apply volume corrections to all the analyses. The distributions of the bolometric luminosity of young stars are compared for both samples: they are found to be consistent with each other for galaxies of intermediate luminosities but some differences are found for high (>5 10^{10} L_sun) luminosities. The shallowness of the IRAS survey prevents us from securing comparison at low luminosities (<2 10^9 L_sun). The ratio of the total infrared (TIR) luminosity to the FUV luminosity is found to increase with the bolometric luminosity in a similar way for both samples up to 5 10^{10} L_sun. Brighter galaxies are found to have a different behavior according to their selection: the L_TIR/L_FUV ratio of the FUV-selected galaxies brighter than 5 10^{10} L_sun reaches a plateau whereas L_TIR/L_FUV continues to increase with the luminosity of bright galaxies selected in FIR. The volume-averaged specific star formation rate (SFR per unit galaxy stellar mass, SSFR) is found to decrease toward massive galaxies within each selection. The SSFR is found to be larger than that measured for optical and NIR-selected sample over the whole mass range for the FIR selection, and for masses larger than 10^{10} M_sun for the FUV selection. Luminous and massive galaxies selected in FIR appear as active as galaxies with similar characteristics detected at z ~ 0.7., Comment: 32 pages, 9 figures, to be published in the Astrophysical Journal Supplement series dedicated to GALEX results

We present images, integrated photometry, surface-brightness and color profiles for a total of 1034 nearby galaxies recently observed by the GALEX satellite in its far-ultraviolet (FUV; 1516A) and near-ultraviolet (NUV; 2267A) bands. (...) This data set has been complemented with archival optical, near-infrared, and far-infrared fluxes and colors. We find that the integrated (FUV-K) color provides robust discrimination between elliptical and spiral/irregular galaxies and also among spiral galaxies of different sub-types. Elliptical galaxies with brighter K-band luminosities (i.e. more massive) are redder in (NUV-K) color but bluer in (FUV-NUV) than less massive ellipticals. In the case of the spiral/irregular galaxies our analysis shows the presence of a relatively tight correlation between the (FUV-NUV) color and the total infrared-to-UV ratio. The correlation found between (FUV-NUV) color and K-band luminosity (with lower luminosity objects being bluer than more luminous ones) can be explained as due to an increase in the dust content with galaxy luminosity. The images in this Atlas along with the profiles and integrated properties are publicly available through a dedicated web page at http://nedwww.ipac.caltech.edu/level5/GALEX_Atlas, Comment: 181 pages, 10 figures, accepted for publication in ApJS (abstract abridged)

We combine data from SDSS and the GALEX and Spitzer observatories to create a sample of galaxies observed homogeneously from the UV to the Far-IR. This sample, consisting of ~460 galaxies observed spectroscopically by SDSS provides a multiwavelength (0.15-24 micron) view of obscured and unobscured star formation in nearby (z<0.3) galaxies with SFRs ranging from 0.01 to 100 M_solar/yr. We calculate a robust dust measure from the infrared to UV ratio (IRX) and explore the influence of star formation history (SFH) on the dust-UV color relation (i.e. the IRX-beta relation). We find that the UV colors of galaxies are only weakly dependent on their SFH as measured by the 4000A break. However, we find that the contributions of dust and SFH are distinguishable when colors at widely separated wavelengths (e.g. 0.23-3.6 micron) are introduced. We show this explicitly by recasting the IRX-beta relation as a more general IRX-SFH-color relation, which we examine in different projections. We also determine simple fits to this relation., Comment: 4 pages, 3 figures, accepted by ApJ Letters

This work presents the main ultraviolet (UV) and far-infrared (FIR) properties of two samples of nearby galaxies selected from the GALEX ($\lambda = 2315$\AA, hereafter NUV) and IRAS ($\lambda = 60\mu$m) surveys respectively. They are built in order to get detection at both wavelengths for most of the galaxies. Star formation rate (SFR) estimators based on the UV and FIR emissions are compared. Systematic differences are found between the SFR estimators for individual galaxies based on the NUV fluxes corrected for dust attenuation and on the total IR luminosity. A combined estimator based on NUV and IR luminosities seems to be the best proxy over the whole range of values of SFR. Although both samples present similar average values of the birthrate parameter b, their star-formation-related properties are substantially different: NUV-selected galaxies tend to show larger values of $b$ for lower masses, SFRs and dust attenuations, supporting previous scenarios for the star formation history (SFH). Conversely, about 20% of the FIR-selected galaxies show high values of $b$, SFR and NUV attenuation. These galaxies, most of them being LIRGs and ULIRGs, break down the downsizing picture for the SFH, however their relative contribution per unit volume is small in the local Universe. Finally, the cosmic SFR density of the local Universe is estimated in a consistent way from the NUV and IR luminosities., Comment: 43 pages, 13 figures, accepted for publication in Astrophysical Journal Supplement Series

We have studied ~2100 early-type galaxies in the SDSS DR3 which have been detected by the GALEX Medium Imaging Survey (MIS), in the redshift range 0 < z < 0.11. Combining GALEX UV photometry with corollary optical data from the SDSS, we find that, at a 95 percent confidence level, at least ~30 percent of galaxies in this sample have UV to optical colours consistent with some recent star formation within the last Gyr. In particular, galaxies with a NUV - r colour less than 5.5 are very likely to have experienced such recent star formation, taking into account the possibility of a contribution to NUV flux from the UV upturn phenomenon. We find quantitative agreement between the observations and the predictions of a semi-analytical LCDM hierarchical merger model and deduce that early-type galaxies in the redshift range 0 < z < 0.11 have ~1 to 3 percent of their stellar mass in stars less than 1 Gyr old. The average age of this recently formed population is ~300 to 500 Myrs. We also find that monolithically evolving galaxies, where recent star formation can be driven solely by recycled gas from stellar mass loss, cannot exhibit the blue colours (NUV - r < 5.5) seen in a significant fraction (~30 percent) of our observed sample., Comment: To appear in GALEX dedicated ApJ issue in December 2007 (accepted June 2006). A version with high-resolution figures can be downloaded at http://www-astro.physics.ox.ac.uk/~skaviraj/PAPERS/uv_cmr.pdf

We use \textit{GALEX} (Galaxy Evolution Explorer) near-UV (NUV) photometry of a sample of early-type galaxies selected in \textit{SDSS} (Sloan Digital Sky Survey) to study the UV color-magnitude relation (CMR). $NUV-r$ color is an excellent tracer of even small amounts ($\sim 1$% mass fraction) of recent ($\la 1$ Gyr) star formation and so the $NUV-r$ CMR allows us to study the effect of environment on the recent star formation history. We analyze a volume-limited sample of 839 visually-inspected early-type galaxies in the redshift range $0.05 < z < 0.10$ brighter than $M_{r}$ of -21.5 with any possible emission-line or radio-selected AGN removed to avoid contamination. We find that contamination by AGN candidates and late-type interlopers highly bias any study of recent star formation in early-type galaxies and that, after removing those, our lower limit to the fraction of massive early-type galaxies showing signs of recent star formation is roughly $30 \pm 3%$ This suggests that residual star formation is common even amongst the present day early-type galaxy population. We find that the fraction of UV-bright early-type galaxies is 25% higher in low-density environments. However, the density effect is clear only in the lowest density bin. The blue galaxy fraction for the subsample of the brightest early-type galaxies however shows a very strong density dependence, in the sense that the blue galaxy fraction is lower in a higher density region., Comment: Accepted for publication in ApJ, paper with high-resolution figures can be downloaded at: http://www-astro.physics.ox.ac.uk/~kevins/PAPERS/uv_environment.ps

We present GALEX NUV (2310 A) and FUV (1530 A) images of the interacting galaxy NGC 4438 (Arp 120) in the center of the Virgo cluster. These images show an extended (20 kpc) tidal tail at the north-west edge of the galaxy previously undetected at other wavelengths, at 15-25 kpc from its nucleus. Except in the nucleus, the UV morphology of NGC 4438 is totally different from the Halpha+[NII] one, more similar to the X-ray emission, confirming its gas cooling origin. We study the star formation history of NGC 4438 combining spectro-photometric data in the UV-visible-near-IR wavelength range with population synthesis and galaxy evolution models. The data are consistent with a recent (~ 10 Myr), instantaneous burst of star formation in the newly discovered UV north-western tail which is significantly younger than the age of the tidal interaction with NGC 4435, dated by dynamical models at ~ 100 Myr ago. Recent star formation events are also present at the edge of the northern arm and in the southern tail, while totally lacking in the other regions, which are dominated by the old stellar population perturbed during the dynamical interaction with NGC 4435. The contribution of this recent starburst to the total galaxy stellar mass is lower than 0.1%, an extremely low value for such a violent interaction. High-velocity, off-center tidal encounters such as that observed in Arp 120 are thus not sufficient to significantly increase the star formation activity of cluster galaxies., Comment: 7 pages, 3 figures, accepted for publication in Astrophysical Journal Letters. High resolution version of Fig. 3 is available at http://www.ociw.edu/~boissier/f3.ps

We study the UV properties of a volume limited sample of early-type galaxies in the Virgo cluster combining new GALEX far- (1530 A) and near-ultraviolet (2310 A) data with spectro-photometric data available at other wavelengths. The sample includes 264 ellipticals, lenticulars and dwarfs spanning a large range in luminosity (M(B)<-15). While the NUV to optical or near-IR color magnitude relations (CMR) are similar to those observed at optical wavelengths, with a monotonic reddening of the color index with increasing luminosity, the (FUV-V) and (FUV-H) CMRs show a discontinuity between massive and dwarf objects. An even more pronounced dichotomy is observed in the (FUV-NUV) CMR. For ellipticals the (FUV-NUV) color becomes bluer with increasing luminosity and with increasing reddening of the optical or near-IR color indices. For the dwarfs the opposite trend is observed. These observational evidences are consistent with the idea that the UV emission is dominated by hot, evolved stars in giant systems, while in dwarf ellipticals residual star formation activity is more common., Comment: 5 pages, 2 figures, 1 table. Accepted for publication in Astrophysical Journal Letters

We present the GALEX NUV (2310 A) and FUV (1530 A) galaxy luminosity functions of the nearby cluster of galaxies A1367 in the magnitude range -20.3< M_AB < -13.3. The luminosity functions are consistent with previous (~ 2 mag shallower) estimates based on the FOCA and FAUST experiments, but display a steeper faint-end slope than the GALEX luminosity function for local field galaxies. Using spectro-photometric optical data we select out star-forming systems from quiescent galaxies and study their separate contributions to the cluster luminosity function. We find that the UV luminosity function of cluster star-forming galaxies is consistent with the field. The difference between the cluster and field LF is entirely due to the contribution at low luminosities (M_AB >-16 mag) of non star-forming, early-type galaxies that are significantly over dense in clusters., Comment: 4 pages, 4 figures, 1 table. Accepted for publication in Astrophysical Journal Letters

We present the GALEX NUV (2310 A) and FUV (1530 A) galaxy luminosity functions of the nearby cluster of galaxies A1367 in the magnitude range -20.3< M_AB < -13.3. The luminosity functions are consistent with previous (~ 2 mag shallower) estimates based on the FOCA and FAUST experiments, but display a steeper faint-end slope than the GALEX luminosity function for local field galaxies. Using spectro-photometric optical data we select out star-forming systems from quiescent galaxies and study their separate contributions to the cluster luminosity function. We find that the UV luminosity function of cluster star-forming galaxies is consistent with the field. The difference between the cluster and field LF is entirely due to the contribution at low luminosities (M_AB >-16 mag) of non star-forming, early-type galaxies that are significantly over dense in clusters., Comment: 4 pages, 4 figures, 1 table. Accepted for publication in Astrophysical Journal Letters